Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Other

Michael R Tota

Sheo B Singh

Jun Wang

Leonardus H T Van Der Ploeg

Doris F Cully

John W Hess

Tung M Fong

William W Ward

Leonardus H Van Der Ploeg

Margaret A Cascieri

Fang Chen

Kathleen A Sullivan

Lin-Lin Shiao

Diana Benincasa

Charles I Rosenblum

Lyndon J Mitnaul

Sajjad A Qureshi

The present technology is directed to the nucleic acid molecule encoding novel fluorescent proteins, in particular, green fluorescent proteins (GFPs), such as those that may be isolated from an organism of genus, as well as compositions comprising the same and methods for analyzing a physiologically active substance in a cell wherein the fluorescent proteins are expressed in the cell.

[object Object]

The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections,infections, malarial infections and other apicomplexan protozoal diseases.

Method of treatment using fatty acid synthesis inhibitors

The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.

Methods of identifying inhibitors of the fusion of two types of cells, particularly when fusion is mediated by the interaction of a viral protein and such cellular proteins as CD4 and chemokine receptors, are disclosed. The methods are suitable for identifying substances that are useful for the treatment and prevention of viral diseases. Particularly preferred methods are useful for the identification of inhibitors of HIV-1 infection.

Cell fusion assays using fluorescence resonance energy transfer

Novel polypeptides derived from the C-terminal region of the human and mouse agouti related transcript (ART) proteins are provided. Also provided are DNA sequences encoding the novel C-terminal polypeptides. The novel C-terminal polypeptides can be used to inhibit the binding of melanocyte stimulating hormones to melanocortin receptors. Methods of identifying inhibitors of the binding of ART protein to melanocortin receptors are also provided.

C-terminal region of agouti-related transcript (ART) protein

A trans-activation assay for leptin is described. Leptin response elements are located proximal to a promoter, and the promoter region is operatively linked to a reporter gene. When leptin binds with the receptor, the reporter gene is transcribed.

Leptin assay

Growing community of inventors

Middletown, NJ, United States of America

Michael R Tota